0000899243-18-025797.txt : 20181002 0000899243-18-025797.hdr.sgml : 20181002 20181002163059 ACCESSION NUMBER: 0000899243-18-025797 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181001 FILED AS OF DATE: 20181002 DATE AS OF CHANGE: 20181002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perkins Adelene Q CENTRAL INDEX KEY: 0001375124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 181101710 MAIL ADDRESS: STREET 1: C/O INFINITY PHARMACEUTICALS, INC. STREET 2: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-01 0 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001375124 Perkins Adelene Q C/O INFINITY PHARMACEUTICALS, INC. 784 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer Common Stock 2018-10-01 4 S 0 5000 2.82 D 609561 D Common Stock 16446.7945 I 401(K) The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017. The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.80 to $2.88, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. Includes 7,309 shares of common stock acquired by Ms. Perkins on June 16, 2018 through participation in the issuer's Employee Stock Purchase Plan. /s/ Adelene Perkins 2018-10-02